ABSTRACT
Purpose To better understand the etiologic pathways in glaucoma, we aimed to identify pre-diagnostic plasma metabolites associated with glaucoma risk.
Methods In a case-control study from the Nurses’ Health Study (NHS), NHSII and Health Professionals Follow-Up Study (HPFS), 599 incident primary open-angle glaucoma (POAG) cases (mean time between blood draw and diagnosis was 10.3 years) were 1:1 matched to 599 controls. Plasma metabolites were measured with LC-MS/MS at the Broad Institute (Cambridge, MA, USA); 367 metabolites from 17 metabolite classes passed quality control analyses. For comparison, in a cross-sectional study in the UK Biobank, 168 NMR metabolites (Nightingale, Finland; version 2020) were measured in serum samples from 2,238 prevalent glaucoma cases and 44,723 controls. Metabolites were probit-score transformed for normality; multiple logistic regression was used to identify metabolites associated with POAG in NHS/NHSII/HPFS and glaucoma in UK Biobank. In NHS/NHSII/HPFS, we also used Metabolite Set Enrichment Analysis to identify metabolite classes associated with POAG. All analyses adjusted for established glaucoma risk factors. False discovery rate (FDR) and number of effective tests (NEF) were used to adjust for multiple comparisons.
Results Nine metabolite classes were associated (FDR<0.05) with POAG in NHS/NHSII/HPFS: triglycerides, diglycerides, two lysophospholipids classes [lysophosphatidylcholines and lysophosphatidylethanolamines], and two phospholipid class [phosphatidylethanolamines and phosphatidylcholines] were positively associated, while cholesteryl esters, carnitines, and organic acids and derivatives were inversely associated with POAG risk; further adjustment for covariates minimally altered the results. These associations were particularly stronger for POAG with paracentral visual field loss. In the UK Biobank, notably, triglycerides and phospholipids (from which lysophospholipids are derived through hydrolysis), were confirmed to be associated (p<0.05) with higher glaucoma risk. Also, in the UK Biobank, the metabolites of tyrosine, glucose, and glutamine were positively associated (NEF<0.2) while 3-hydroxybutyrate, acetate, citrate, pyruvate, and lactate (the latter 4 being anionic organic acids) were inversely associated with glaucoma (NEF<0.05).
Conclusions Higher levels of glycerides (diglycerides and triglycerides) and phospholipids were adversely associated with glaucoma in both the NHS/NHSII/HPFS and the UK Biobank, suggesting that they play an important role in glaucoma pathogenesis.
PRÉCIS Higher glyceride and phospholipid levels in pre-diagnostic plasma was associated with glaucoma risk in three cohorts and were associated with prevalent glaucoma in the UK Biobank. Altered lipid metabolism may be etiologically important in glaucoma.
Competing Interest Statement
Dr. Pasquale is a consultant to Eyenovia, Twenty twenty and Skye Biosciences. Dr. Wiggs is a consultant to Allergan, Avellino, Editas, Maze, Regenxbio and has received research support from Aerpio. Dr Khawaja is a consultant to Abbvie, Aerie, Google Health, Novartis, Reichert, Santen and Thea.
Funding Statement
This work was supported by grants from the National Institutes of Health: R01 EY015473 (LRP), NCI UM1 CA186107, U01 CA167552, U01 CA176726, R01 CA49449, R01 CA67262 and an unrestricted challenge grant to Icahn School of Medicine at Mount Sinai, Department of Ophthalmology from Research to Prevent Blindness (LRP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. APK is supported by a UK Research and Innovation Future Leaders Fellowship (Medical Research Council MR/T040912/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the institutional review boards (IRBs) of the Brigham and Womens Hospital, Harvard T.H. Chan School of Public Health and Icahn School of Medicine at Mount Sinai.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Information including the procedures to obtain and access data from the Nurses Health Studies and Health Professionals Follow-up Study is described at https://www.nurseshealthstudy.org/researchers (contact email: nhsaccess{at}channing.harvard.edu) and https://sites.sph.harvard.edu/hpfs/for-collaborators/
